HRP20150934T1 - Djelovanje na abcb5 u terapiji raka - Google Patents

Djelovanje na abcb5 u terapiji raka Download PDF

Info

Publication number
HRP20150934T1
HRP20150934T1 HRP20150934TT HRP20150934T HRP20150934T1 HR P20150934 T1 HRP20150934 T1 HR P20150934T1 HR P20150934T T HRP20150934T T HR P20150934TT HR P20150934 T HRP20150934 T HR P20150934T HR P20150934 T1 HRP20150934 T1 HR P20150934T1
Authority
HR
Croatia
Prior art keywords
seq
antibody
amino acid
acid sequence
variable domain
Prior art date
Application number
HRP20150934TT
Other languages
English (en)
Croatian (hr)
Inventor
Markus H. Frank
Natasha Y. Frank
Mohamed H. Sayegh
Original Assignee
The Brigham And Women's Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women's Hospital, Inc. filed Critical The Brigham And Women's Hospital, Inc.
Publication of HRP20150934T1 publication Critical patent/HRP20150934T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • G01N33/575—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02022—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2) rRNA N-glycosylase (3.2.2.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
HRP20150934TT 2007-04-12 2008-04-11 Djelovanje na abcb5 u terapiji raka HRP20150934T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92312807P 2007-04-12 2007-04-12
US705907P 2007-12-11 2007-12-11
PCT/US2008/004715 WO2008127656A1 (en) 2007-04-12 2008-04-11 Targeting abcb5 for cancer therapy
EP08742787.8A EP2155248B1 (en) 2007-04-12 2008-04-11 Targeting abcb5 for cancer therapy

Publications (1)

Publication Number Publication Date
HRP20150934T1 true HRP20150934T1 (hr) 2015-11-06

Family

ID=39661432

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150934TT HRP20150934T1 (hr) 2007-04-12 2008-04-11 Djelovanje na abcb5 u terapiji raka
HRP20181385TT HRP20181385T1 (hr) 2007-04-12 2018-08-28 Ciljanje abcb5 za terapiju raka

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181385TT HRP20181385T1 (hr) 2007-04-12 2018-08-28 Ciljanje abcb5 za terapiju raka

Country Status (15)

Country Link
US (4) US7928202B2 (enExample)
EP (3) EP2644205B1 (enExample)
JP (4) JP5889527B2 (enExample)
AU (1) AU2008239633B2 (enExample)
CA (1) CA2718573C (enExample)
CY (2) CY1116823T1 (enExample)
DK (2) DK2644205T3 (enExample)
ES (2) ES2547016T3 (enExample)
HR (2) HRP20150934T1 (enExample)
HU (2) HUE027593T2 (enExample)
LT (1) LT2644205T (enExample)
PL (2) PL2155248T3 (enExample)
PT (2) PT2644205T (enExample)
SI (2) SI2155248T1 (enExample)
WO (1) WO2008127656A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140868D1 (de) * 2000-06-05 2010-02-04 Brigham & Womens Hospital Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
PL2772535T3 (pl) * 2006-05-31 2022-09-05 Children's Medical Center Corporation Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory
EP2644205B1 (en) 2007-04-12 2018-06-13 The Brigham and Women's Hospital, Inc. Targeting ABCB5 for cancer therapy
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010065711A1 (en) * 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
US20110280862A1 (en) * 2010-05-14 2011-11-17 The University Of Hong Kong Gep and drug transporter regulation, cancer therapy and prognosis
ES2860573T3 (es) 2013-02-19 2021-10-05 Childrens Medical Center Células madre ABCB5(+) para el tratamiento de enfermedades oculares
CN105517587B (zh) 2013-05-10 2019-02-19 儿童医学中心公司 伤口愈合与组织工程
US9177410B2 (en) 2013-08-09 2015-11-03 Ayla Mandel System and method for creating avatars or animated sequences using human body features extracted from a still image
US20180134771A1 (en) * 2015-05-07 2018-05-17 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
AU2016293674B2 (en) 2015-07-16 2019-11-21 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2019210109A1 (en) * 2018-04-25 2019-10-31 Children's Medical Center Corporation Abcb5 ligands and substrates
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
JP2023522047A (ja) * 2020-04-15 2023-05-26 ザ チルドレンズ メディカル センター コーポレーション 多形性膠芽腫におけるａｂｃｂ５の標的化
US20230203153A1 (en) * 2020-04-30 2023-06-29 Children's Medical Center Corporation Antibodies specific to abcb5 and uses thereof
CN116836291B (zh) * 2023-08-25 2023-11-07 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565354A (en) 1896-08-04 James h
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
WO1980001139A1 (en) 1978-12-06 1980-06-12 Svedman Paul Device for treating tissues,for example skin
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
AT379688B (de) 1982-11-22 1986-02-10 List Hans Sensorelement zur bestimmung des o2-gehaltes einer probe
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0174810B1 (en) 1984-09-10 1993-07-21 HSC Research Development Corporation Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna
US4837306A (en) 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
GB8509978D0 (en) 1985-04-18 1985-05-30 Juhasz L Wound dressings
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5565354A (en) 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5399483A (en) 1989-03-30 1995-03-21 Suntory Limited Expression of MDR-related gene in yeast cell
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5434075A (en) 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6436078B1 (en) 1994-12-06 2002-08-20 Pal Svedman Transdermal perfusion of fluids
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
IT1257893B (it) 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
GB2272645B8 (en) 1992-11-23 2010-02-10 Johnson & Johnson Medical Wound dressing
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
AU704183B2 (en) 1994-01-05 1999-04-15 Arqule, Inc. Systematic modular production of aminimide- and oxazolone-based molecules having selected properties
GB9403135D0 (en) 1994-02-18 1994-04-06 Univ Glasgow Wound healing device
CA2190121A1 (en) 1994-03-15 1995-09-21 Edith Mathiowitz Polymeric gene delivery system
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2259386C (en) * 1996-06-28 2002-06-25 Matsushita Electric Works, Ltd. Modification apparatus
US5904659A (en) 1997-02-14 1999-05-18 Exogen, Inc. Ultrasonic treatment for wounds
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
DE19722075C1 (de) 1997-05-27 1998-10-01 Wilhelm Dr Med Fleischmann Vorrichtung zur Applikation von Wirkstoffen an einer Wundoberfläche
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
US6071267A (en) 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
GB9808836D0 (en) 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
JP4220058B2 (ja) 1998-06-30 2009-02-04 浜松ホトニクス株式会社 半導体位置検出器
US6479072B1 (en) 1999-02-11 2002-11-12 The General Hospital Corporation Microfabricated membranes and matrices
US6277574B1 (en) 1999-04-09 2001-08-21 Incyte Genomics, Inc. Genes associated with diseases of the kidney
ES2307552T3 (es) 1999-11-29 2008-12-01 Hill-Rom Services, Inc. Aparato de tratamiento de heridas.
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
DE60140868D1 (de) 2000-06-05 2010-02-04 Brigham & Womens Hospital Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
US6930169B2 (en) * 2000-06-12 2005-08-16 University Of Baltimore Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
BR0112272A (pt) 2000-06-22 2003-05-06 Genentech Inc Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratamento de neuropatia ou doença neurodegenerativa ou reparo de uma célula nervosa lesionada, método para aumentar a proliferação, manutenção ou regeneração de neurÈnios periféricos, método para o tratamento de doença ou condição que envolve a degeneração celular em um paciente mamìfero, método de indução de angiogênese, método de fabricação de um anticorpo anti-trkc, usos de um anticorpo
EP1322936A2 (en) 2000-10-03 2003-07-02 California Institute Of Technology Microfluidic devices and methods of use
AU2002241569A1 (en) 2000-10-27 2002-05-27 Incyte Genomics, Inc. Transporters and ion channels
US6855135B2 (en) 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US6685681B2 (en) 2000-11-29 2004-02-03 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US8015677B2 (en) 2000-12-01 2011-09-13 Aard-Balm Limited Embalming fluid
WO2002053290A2 (en) 2001-01-08 2002-07-11 President And Fellows Of Harvard College Valves and pumps for microfluidic systems and method for making microfluidic systems
US6899873B2 (en) 2001-02-02 2005-05-31 The Regents Of The University Of Michigan Method of forming micro-tubular polymeric materials
WO2002083046A1 (en) 2001-04-16 2002-10-24 Pamela Howard Wound dressing system
EP2623138B1 (en) 2001-12-26 2020-08-05 KCI Licensing, Inc. Vented vacuum bandage with irrigation for wound healing and method
WO2003057307A1 (en) 2001-12-26 2003-07-17 Hill-Rom Services, Inc. Wound vacuum therapy dressing kit
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
SI1578446T1 (sl) 2002-11-07 2015-07-31 Immunogen, Inc. Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0325130D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with scaffold
WO2005054445A1 (en) 2003-11-24 2005-06-16 The Rockefeller University A method for isolating a self-renewing, multipotent slow-cycling cell
SI1704166T1 (sl) 2004-01-07 2015-06-30 Novartis Vaccines And Diagnostics, Inc. M-scf specifiäśno monoklonsko protitelo in uporabe le-tega
WO2005079257A2 (en) 2004-02-12 2005-09-01 Dexcom, Inc. Biointerface with macro- and micro- architecture
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
CA2629330C (en) 2004-11-12 2018-05-22 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2612021A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
PL2772535T3 (pl) 2006-05-31 2022-09-05 Children's Medical Center Corporation Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory
EP2526969A1 (en) 2006-09-07 2012-11-28 Stemline Therapeutics, Inc. Monitoring cancer stem cells
EP2644205B1 (en) 2007-04-12 2018-06-13 The Brigham and Women's Hospital, Inc. Targeting ABCB5 for cancer therapy
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
ES2860573T3 (es) 2013-02-19 2021-10-05 Childrens Medical Center Células madre ABCB5(+) para el tratamiento de enfermedades oculares
CN105517587B (zh) 2013-05-10 2019-02-19 儿童医学中心公司 伤口愈合与组织工程

Also Published As

Publication number Publication date
PT2644205T (pt) 2018-10-19
JP6530044B2 (ja) 2019-06-12
JP2010534191A (ja) 2010-11-04
EP3431103A1 (en) 2019-01-23
SI2155248T1 (sl) 2015-12-31
AU2008239633A1 (en) 2008-10-23
US20160136297A1 (en) 2016-05-19
JP2014133770A (ja) 2014-07-24
JP2016188248A (ja) 2016-11-04
DK2155248T3 (en) 2015-09-14
US9855342B2 (en) 2018-01-02
CA2718573C (en) 2020-07-14
EP2155248B1 (en) 2015-06-10
EP3431103B1 (en) 2021-07-28
DK2644205T3 (en) 2018-09-24
LT2644205T (lt) 2018-12-10
SI2644205T1 (sl) 2018-11-30
ES2547016T3 (es) 2015-09-30
CY1116823T1 (el) 2017-03-15
US20110165149A1 (en) 2011-07-07
JP2018052979A (ja) 2018-04-05
HUE027593T2 (en) 2016-11-28
PL2644205T3 (pl) 2018-11-30
US20140302031A1 (en) 2014-10-09
EP2155248A1 (en) 2010-02-24
CY1121046T1 (el) 2019-12-11
CA2718573A1 (en) 2008-10-23
AU2008239633B2 (en) 2014-05-29
JP5889527B2 (ja) 2016-03-22
ES2687270T3 (es) 2018-10-24
JP6268237B2 (ja) 2018-01-24
PT2155248E (pt) 2015-10-23
EP2644205B1 (en) 2018-06-13
US7928202B2 (en) 2011-04-19
US9266946B2 (en) 2016-02-23
EP2644205A1 (en) 2013-10-02
US20090117117A1 (en) 2009-05-07
HRP20181385T1 (hr) 2018-10-19
US8697072B2 (en) 2014-04-15
WO2008127656A1 (en) 2008-10-23
HUE039385T2 (hu) 2018-12-28
PL2155248T3 (pl) 2015-12-31

Similar Documents

Publication Publication Date Title
HRP20150934T1 (hr) Djelovanje na abcb5 u terapiji raka
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
EA201401134A1 (ru) Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
AU2015238264B2 (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
JP2015524821A5 (enExample)
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
AR077088A1 (es) Proteinas biespecificas de union a antigeno
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
EA200970879A1 (ru) Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
PE20210377A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
JP2017504578A5 (enExample)
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
WO2017060322A3 (en) Ptefb-inhibitor-adc
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
HRP20251051T1 (hr) Anti-cd3 antitijelo i molekula koja sadrži navedeno antitijelo
HK1252998A1 (zh) Prame肽专一性类t细胞受体抗体
IL295295A (en) Antibodies targeting fc receptor-like 5 and methods of use
HRP20200679T1 (hr) Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji
PE20120475A1 (es) Anticuerpos especificos para dkk-1
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
JP2013506428A5 (enExample)
HRP20240415T1 (hr) Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba